Polymorphisms in the <scp>NF</scp>kB, <scp>TNF</scp>‐alpha, <scp>IL</scp>‐1beta, and <scp>IL</scp>‐18 pathways are associated with response to anti‐<scp>TNF</scp> therapy in Danish patients with inflammatory bowel disease

Abstract

The results support that polymorphisms in genes involved in the regulation of the NFκB pathway (TLR2, TLR4, and NFKBIA), the TNF-α signalling pathway (TNFRSF1A), and other cytokine pathways (NLRP3, IL1RN, IL18, and JAK2) were associated with response to anti-TNF therapy. Our multi-SNP model predicted response rate of more than 82% (in 9% of the CD patients) and 75% (in 15% of the UC patients), compared to 71% and 64% in all CD and UC patients, respectively. More studies are warranted to predict response for use in the clinic.